133 related articles for article (PubMed ID: 33858507)
1. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
[TBL] [Abstract][Full Text] [Related]
2. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
[TBL] [Abstract][Full Text] [Related]
3. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis.
Moloudi K; Neshasteriz A; Hosseini A; Eyvazzadeh N; Shomali M; Eynali S; Mirzaei E; Azarnezhad A
Iran Biomed J; 2017 Sep; 21(5):330-7. PubMed ID: 28459147
[TBL] [Abstract][Full Text] [Related]
5. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium.
Sheth AI; Althoff MJ; Tolison H; Engel K; Amaya ML; Krug AE; Young TN; Minhajuddin M; Pei S; Patel SB; Winters A; Miller R; Shelton IT; St-Germain J; Ling T; Jones CL; Raught B; Gillen AE; Ransom M; Staggs S; Smith CA; Pollyea DA; Stevens BM; Jordan CT
Cancer Discov; 2024 May; ():. PubMed ID: 38787341
[TBL] [Abstract][Full Text] [Related]
6. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium.
Sheth AI; Engel K; Tolison H; Althoff MJ; Amaya ML; Krug A; Young T; Pei S; Patel SB; Minhajuddin M; Winters A; Miller R; Shelton I; St-Germain J; Ling T; Jones C; Raught B; Gillen A; Ransom M; Staggs S; Smith CA; Pollyea DA; Stevens BM; Jordan CT
bioRxiv; 2023 Oct; ():. PubMed ID: 37873284
[TBL] [Abstract][Full Text] [Related]
7. SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming.
Xu X; Yu Y; Zhang W; Ma W; He C; Qiu G; Wang X; Liu Q; Zhao M; Xie J; Tao F; Perry JM; Liu Q; Rao S; Kang X; Zhao M; Jiang L
Nat Cell Biol; 2024 Mar; 26(3):464-477. PubMed ID: 38321204
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of
Tari K; Nasimian A; Kazi JU; Abroun S
Int J Mol Cell Med; 2023; 12(3):229-241. PubMed ID: 38751657
[TBL] [Abstract][Full Text] [Related]
9. Pityriasiform drug eruption associated with venetoclax for acute myeloid leukaemia.
Liu TJ; McMeniman EK
Anticancer Drugs; 2024 Mar; ():. PubMed ID: 38527223
[TBL] [Abstract][Full Text] [Related]
10. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
Flanagan L; Coughlan A; Cosgrove N; Roe A; Wang Y; Gilmore S; Drozdz I; Comerford C; Ryan J; Minihane E; Parvin S; O'Dwyer M; Quinn J; Murphy P; Furney S; Glavey S; Chonghaile TN; ; ;
Haematologica; 2024 Mar; ():. PubMed ID: 38511268
[TBL] [Abstract][Full Text] [Related]
11. Piplartine eliminates CD34 + AML stem/progenitor cells by inducing oxidative stress and suppressing NF-κB signalling.
Rodrigues ACBDC; Silva SLR; Dias IRSB; Costa RGA; Oliveira MS; Soares MBP; Dias RB; Valverde LF; Rocha CAG; Johnson EM; Pina C; Bezerra DP
Cell Death Discov; 2024 Mar; 10(1):147. PubMed ID: 38503729
[TBL] [Abstract][Full Text] [Related]
12. MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
Zhang X; Zhong Y; Liu L; Suo S; Zhao S; Xiao F; Qin J; Tong H; Jin J; Yu W
Br J Haematol; 2024 Apr; ():. PubMed ID: 38685592
[No Abstract] [Full Text] [Related]
13. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
14. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.
van Gils N; Denkers F; Smit L
Front Oncol; 2021; 11():659253. PubMed ID: 34012921
[TBL] [Abstract][Full Text] [Related]
15. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
16. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
17. Targeting epigenetic mechanisms to overcome venetoclax resistance.
Prado G; Kaestner CL; Licht JD; Bennett RL
Biochim Biophys Acta Mol Cell Res; 2021 Jul; 1868(8):119047. PubMed ID: 33945824
[TBL] [Abstract][Full Text] [Related]
18. Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia.
Zhang X; Qian J; Wang H; Wang Y; Zhang Y; Qian P; Lou Y; Jin J; Zhu H
Biomark Res; 2021 May; 9(1):30. PubMed ID: 33933163
[TBL] [Abstract][Full Text] [Related]
19. Hormone autocrination by vascularized hydrogel delivery of ovary spheroids to rescue ovarian dysfunctions.
Yoon HJ; Lee YJ; Baek S; Chung YS; Kim DH; Lee JH; Shin YC; Shin YM; Ryu C; Kim HS; Ahn SH; Kim H; Won YB; Lee I; Jeon MJ; Cho SH; Lee BS; Sung HJ; Choi YS
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33910892
[TBL] [Abstract][Full Text] [Related]
20. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
